LIVERFAStTM is a noninvasive panel of tests, combining patient’s age, gender and body mass index with 10 blood biomarkers; correlated with liver conditions to generate three scores for estimating fibrosis, activity and steatosis.

For each condition, LIVERFAStTM evaluates a quantitative score (0.00 to 1.00) and its estimated grade or stage, similar to the liver biopsy classification.

LIVERFAStTM algorithm uses AI neural networks to optimize the clinical diagnosis according to the latest NAFLD histopathologic SAF scoring system, that covers the entire spectrum of lesions (from S0-A0-F0 to S3-A4-F4) and provides an activity score not biased by steatosis.